BioSig Technologies terminates ATM sales agreement

In a regulatory filing, BioSig Technologies stated that, as previously disclosed, on May 17, the company entered into an ATM sales agreement with Virtu Americas LLC to act as the company’s sales agent or principal with respect to the issuance and sale of up to $10M of the company’s shares of common stock from time to time in an at-the-market public offering. On November 30, the company delivered written notice to the agent to terminate the sales agreement, effective December 1, the filing stated. The company is not subject to any termination penalties related to the termination of the sales agreement. Prior to termination, approximately $7.8M in shares of common stock remained available for sale under the agreement, the filing noted.